Szemészet, 2019 (156. évfolyam, 1-4. szám)

2019-12-01 / 4. szám

Factors influencing

outcomes after vitrectomy for proliferative diabetic retinopathy

8. Sato

T, Tsuboi K, Nakashima H, et al. Characteristics of cases with postoperative vitreous hemorrhage after 25-gauge vitrectomy for repair of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2017; 255: 665-671.

9. Aiello

LR Ayala AR, Antoszyk AN, et al. Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control: A Randomized Clinical Trial. JAMA Ophthalmol 2015; 133: 888-96.

10. Zehetner

C, Kirchmair R, Kralinger

M,

et al. Correlation of vascular endothelial growth factor plasma levels and glycemic control in patients with diabetic retinopathy. Acta Ophthalmol 2013; 91: e470-3.

11. Tonello

M, Costa RA, Almeida FR

et al.

Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008; 86: 385-9.

12. Figueira

J, Fletcher E, Massin R et al. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High- Risk Proliferative Diabetic Retinopathy (PROTEUS Study). Ophthalmology 2018; 125: 691-700.

13. Sivaprasad

S, Prevost AT, Vasconcelos JC, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet 2017; 389: 2193-2203.

14. Nicholson

L, Crosby-Nwaobi R, Vasconcelos JC, et al. Mechanistic Evaluation of Panretinal Photocoagulation Versus Aflibercept in Proliferative Diabetic Retinopathy: CLARITY Substudy. Invest Ophthalmol Vis Sei

2018;

59: 4277-4284.

15. Nicholson

L, Ramu J, Chan EW, et al. Retinal Nonperfusion Characteristics on Ultra-Widefield Angiography in Eyes With Severe Nonproliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy. JAMA Ophthalmol 2019; 137: 626-631.

16. Early

vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group. Arch Ophthalmol 1985; 103: 1644-52.

17. Simunovic

MR Maberley DA. Anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy: A Systematic Review and Meta-Analysis. Retina 2015; 35: 1931-42.

18. Zhang

ZH, Liu HY,

Hernandez-Da

Mota SE, et al. Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials. Am J Ophthalmol 2013; 156: 106-115.e2.

19. Zhao

X-y, Xia S, and ChenY-x. Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials. British Journal of Ophthalmology 2018; 102: 1077.

20. Lee

BJ and Yu HG. Vitreous hemorrhage after the 25-gauge transconjunctival sutureless vitrectomy for proliferative diabetic retinopathy. Retina 2010; 30: 1671-7.

21. Oshima

Y, Shima 0, Wakabayashi T, Kusaka S, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 2009; 116:927-38.

22. Motoda

S, Shiraki

N,

Ishihara T, et al. Predictors of postoperative bleeding after vitrectomy for vitreous hemorrhage in patients with diabetic retinopathy. 2018; 9: 940-945.

23. Hershberger

VS, Augsburger

JJ,

Hutchins RK, et al. Fibrovascular ingrowth at sclerotomy sites in vitrectomized diabetic eyes with recurrent vitreous hemorrhage: ultrasound biomicroscopy findings. Ophthalmology 2004; 111: 1215-21.

24. Yang

CM, Yeh PT, and Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology 2007; 114: 710-5.

25. Yoshida

S, Kubo Y, Kobayashi Y, et al. Increased vitreous concentrations of MCP-1 and IL-6 after vitrectomy in patients with proliferative diabetic retinopathy: possible association with postoperative macular oedema. British Journal of Ophthalmology 2015; 99: 960-966.

26. Naithani

R Puranik S, Vashisht N, et al. Role of topical nepafenac in prevention and treatment of macular edema after vitreoretinal surgery. Retina 2012; 32: 250-255.

27. Jung

YH, Lee Y. Efficacy of vitrectomy combined with an intraoperative dexamethasone implant in refractory diabetic macular edema. Acta Diabetologica 2019; 56: 691-696.

28. Elman

MJ, Ayala A, Bressler NM, et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015; 122: 375-81.

29. Elman

MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609—14.

30. Diabetic

Retinopathy Clinical Research N, Chew E, Strauber

S,

et al. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. Ophthalmology 2007; 114: 1190-1196.

31. Jampol

LM, Glassman AR, and Bressler NM. Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network. JAMA Ophthalmol 2015; 133: 983-4.

32. Ross

EL, Hutton DW, Stein JD, et al. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. JAMA Ophthalmol 2016: 134: 888-96.

33. Wells

JA,

Glassman

AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med, 2015; 372: 1193-203.

34. Maturi

RK,

Glassman AR, Liu D, et al. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol 2018; 136: 29-38.

35. Vértes

A. Egyéves halálozás miokardiális infarktus után (Myocardial

infarction mortality after one year). Cardiologia Hungarica 2017; 47: 436-438.

36. Cukorbetegség

miatti halálozás, nemenként (2011-2016). (cited

2019 10 July);

Available from: eurostat_tablalVtabl/tps00137.html.

https://www.ksh.hu/docs/hun/

37. Randomized

clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol 2013; 131: 283-93.

38. Gross

JG, Glassman AR, Jampol LM, et al. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. Jama 2015; 314: 2137-46.

39. Gross

JG, Glassman AR, Liu D, et al. and Network ftDRCR. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA Ophthalmology 2018; 136: 1138-1148.

40. Scott

IU, Danis RR Bressler SB, et al. Effect of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center-involved diabetic macular edema. Retina 2009; 29: 613-7.

41. The

course of response to focal/grid photocoagulation for diabetic macular edema. Retina 2009; 29: 1436-43.

42. Ip

MS, Bressler SB, Antoszyk AN, et al. () A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina 2008; 28: 919-30.

43. Scott

IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114: 1860-7.

44. Diabetic

Retinopathy Clinical Research N, Googe J, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina (Philadelphia, Pa.), 2011; 31: 1009-1027.

45. Baker

CW, Glassman AR, Beaulieu WT, et al. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. Jama 2019; 321: 1880-18

Levelezési ci

Dr Récsán

Zsuzsanna, Semmelweis Egyetem, Szemészeti Klinika

1085 Budapest, Mária u. 39., e-mail: zsrecsan@gmail.com

■298;